Berberine Derivative NBD-125 for Obesity Drug Bioavailability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing obesity treatments, including drugs like thyroid extract and amphetamine, have limited efficacy and safety, and berberine's low solubility and bioavailability hinder its clinical application for weight management.

Innovation Solution

The use of berberine derivative NBD-125 in drug formulation to inhibit weight gain, enhance metabolism and heat production, and prevent white adipose production, while improving solubility and bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If berberine is used for weight loss treatment, then weight loss effect is achieved, but solubility and bioavailability are extremely low

Engineering Contradiction:

Improveweight loss effectVSAvoidsolubility and bioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by chemically modifying berberine to create derivative compounds with altered molecular structures. Specifically, the invention introduces different substituents at the C10 position of the berberine core structure, changing the chemical parameters to improve solubility and bioavailability while maintaining the weight loss efficacy through retained pharmacological activity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite chemical structures by combining the berberine core with various functional groups and substituents. The derivative compounds represent composite molecular structures that integrate the pharmacologically active berberine framework with solubility-enhancing moieties, achieving a balance between efficacy and bioavailability.

Inventive Principle:

Principle #40Composite materials

2Reliability

If existing obesity drugs (thyroid extract, amphetamine) are used, then weight loss can be achieved, but efficacy and safety are not ideal

Engineering Contradiction:

Improveweight loss efficacyVSAvoidsafety issues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent develops novel berberine derivative compounds that serve as alternative obesity treatments with potentially fewer safety concerns. By creating new chemical entities with modified structures, the invention aims to provide shorter-acting, safer alternatives to established drugs like amphetamine, reducing long-term safety risks while maintaining weight loss efficacy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent modifies the chemical parameters of berberine to create derivatives with improved safety profiles. By adjusting molecular structure, substitution patterns, and chemical properties, the invention seeks to optimize the therapeutic window of obesity medications, reducing harmful effects while preserving weight loss benefits.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260053793A1Use of berberine derivative NBD-125 in preparation of drug for preventing and/or treating obesity

Publication Date: 2026.02.26 XIAMEN DANNING TRADITIONAL CHINESE MEDICINE RESEARCH INSTITUTE CO LTD

AI summary

The use of a berberine derivative NBD-125 in preparation of a drug for preventing and/or treating obesity is provided, belonging to the technical field of obesity treatment. Use of a berberine derivative NBD-125 in preparation of a drug for preventing and/or treating obesity is provided. The berberine derivative NBD-125 can prevent and/or treat obesity, with an effect significantly better than that of berberine. Moreover, the berberine derivative NBD-125 can inhibit weight gain, enhance metabolism and/or heat production, inhibit white adipose production, and inhibit differentiation of a preadipocyte into an adipocyte and/or lipid accumulation, where each inhibition index is better than that of the berberine.